Biogen News and Research

RSS
Probiodrug AG, collaborators explain interplay of key suspects in Alzheimer’s

Probiodrug AG, collaborators explain interplay of key suspects in Alzheimer’s

Biogen Idec first quarter revenues increase 7% to $1.3 billion

Biogen Idec first quarter revenues increase 7% to $1.3 billion

Elan first quarter total revenue increases 17% to $288.4 million

Elan first quarter total revenue increases 17% to $288.4 million

Biogen Idec announces positive data from oral BG-12 second Phase 3 trial on RRMS

Biogen Idec announces positive data from oral BG-12 second Phase 3 trial on RRMS

Biogen Idec launches FAMPYRA in Canada

Biogen Idec launches FAMPYRA in Canada

Alzheimer's Association awards $4.2M grant to DIAN-Therapeutic Trials Unit

Alzheimer's Association awards $4.2M grant to DIAN-Therapeutic Trials Unit

Biogen Idec announces new easier to use injection for multiple sclerosis

Biogen Idec announces new easier to use injection for multiple sclerosis

Biogen Idec receives FDA approval for two separate dosing innovations to treat MS

Biogen Idec receives FDA approval for two separate dosing innovations to treat MS

Biogen Idec, Samsung Biologics establish joint venture to develop and market biosimilars

Biogen Idec, Samsung Biologics establish joint venture to develop and market biosimilars

Acorda's fourth quarter GAAP net income increases to $12.7 million

Acorda's fourth quarter GAAP net income increases to $12.7 million

Elan fourth quarter total revenue increases 18% to $271.0 million

Elan fourth quarter total revenue increases 18% to $271.0 million

Biogen Idec 2011 total revenues increase 7% to $5.0 billion

Biogen Idec 2011 total revenues increase 7% to $5.0 billion

Multiple sclerosis drug Gilenya under investigation by FDA and EMA

Multiple sclerosis drug Gilenya under investigation by FDA and EMA

FDA approves product label change for Biogen Idec's TYSABRI to treat MS

FDA approves product label change for Biogen Idec's TYSABRI to treat MS

Probiodrug secures EUR 15M for clinical development of PQ912

Probiodrug secures EUR 15M for clinical development of PQ912

ALS TDI, Biogen Idec and UCB enter agreement to study anti-CD40L antibody for ALS

ALS TDI, Biogen Idec and UCB enter agreement to study anti-CD40L antibody for ALS

Biogen, Samsung partner to develop and market biosimilars

Biogen, Samsung partner to develop and market biosimilars

Nature Medicine publishes dexpramipexole Phase 2 ALS study results

Nature Medicine publishes dexpramipexole Phase 2 ALS study results

Phase III study of BG-12 in relapsing-remitting multiple sclerosis sparks excitement

Phase III study of BG-12 in relapsing-remitting multiple sclerosis sparks excitement

Acorda third quarter GAAP net income increases to $18.9 million

Acorda third quarter GAAP net income increases to $18.9 million